Avoro Capital Advisors LLC Monte Rosa Therapeutics, Inc. Transaction History
Avoro Capital Advisors LLC
- $6.18 Billion
- Q1 2025
A detailed history of Avoro Capital Advisors LLC transactions in Monte Rosa Therapeutics, Inc. stock. As of the latest transaction made, Avoro Capital Advisors LLC holds 4,645,548 shares of GLUE stock, worth $27.4 Million. This represents 0.35% of its overall portfolio holdings.
Number of Shares
4,645,548
Previous 4,345,000
6.92%
Holding current value
$27.4 Million
Previous $30.2 Million
28.52%
% of portfolio
0.35%
Previous 0.44%
Shares
8 transactions
Others Institutions Holding GLUE
# of Institutions
108Shares Held
53.4MCall Options Held
69.1KPut Options Held
22.4K-
Nea Management Company, LLC Timonium, MD7.69MShares$45.4 Million3.39% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD6.64MShares$39.2 Million0.0% of portfolio
-
Bvf Inc San Francisco, CA5.66MShares$33.4 Million1.15% of portfolio
-
Versant Venture Management, LLC San Francisco, CA5.65MShares$33.4 Million54.61% of portfolio
-
Baker Bros. Advisors LP New York, NY4.92MShares$29 Million0.27% of portfolio
About Monte Rosa Therapeutics, Inc.
- Ticker GLUE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,713,900
- Market Cap $276M
- Description
- Monte Rosa Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. It develops an oral molecular glue degrader for GSPT1, a translational termination factor and degron-containing prot...